| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30783f5e0439f26fb23d0089d47f0ea6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-1486
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N15-14 |
| filingDate |
2022-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42f2060f0381e757d1d7d511d8409cb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b008d9d3f47f4a9ea01826911fdfc38a |
| publicationDate |
2022-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-115166250-A |
| titleOfInvention |
Application of T cells as biomarkers in monitoring or predicting the efficacy of anti-HBV therapy or predicting the risk of relapse |
| abstract |
The invention discloses the application of T cells as biomarkers in the preparation of products for monitoring or predicting the curative effect of anti-HBV treatment, the T cells include Treg cells, CD4+T cells and CD8+T cells; and T cells are also disclosed. Application of cells as biomarkers in the preparation of products for predicting the risk of relapse after clinical functional cure in anti-HBV therapy, the T cells include CD8+ subset CXCR5+CD8+ T cells and CD4+ subset CXCR5+CD4+ T cells. The invention can be applied to guide the chronic hepatitis B interferon antiviral therapy, provides a new immune target for exploring the chronic hepatitis B antiviral therapy, improves the cure rate and reduces the recurrence rate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115040538-A |
| priorityDate |
2022-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |